KLSE (MYR): DPHARMA (7148)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
1.24
Today's Change
0.00 (0.00%)
Day's Change
1.22 - 1.25
Trading Volume
680,600
Market Cap
1,193 Million
NOSH
962 Million
Latest Quarter
30-Jun-2024 [#2]
Announcement Date
15-Aug-2024
Next Quarter
30-Sep-2024
Est. Ann. Date
08-Nov-2024
Est. Ann. Due Date
29-Nov-2024
QoQ | YoY
9.24% | 33.08%
Revenue | NP to SH
748,028.000 | 49,438.000
RPS | P/RPS
77.76 Cent | 1.59
EPS | P/E | EY
5.14 Cent | 24.13 | 4.14%
DPS | DY | Payout %
2.80 Cent | 2.26% | 54.48%
NAPS | P/NAPS
0.72 | 1.72
QoQ | YoY
9.16% | -28.02%
NP Margin | ROE
6.61% | 7.14%
F.Y. | Ann. Date
30-Jun-2024 | 15-Aug-2024
Latest Audited Result
31-Dec-2023
Announcement Date
26-Apr-2024
Next Audited Result
31-Dec-2024
Est. Ann. Date
26-Apr-2025
Est. Ann. Due Date
29-Jun-2025
Revenue | NP to SH
704,727.000 | 52,645.000
RPS | P/RPS
73.26 Cent | 1.69
EPS | P/E | EY
5.49 Cent | 22.66 | 4.41%
DPS | DY | Payout %
2.30 Cent | 1.85% | 42.03%
NAPS | P/NAPS
0.71 | 1.75
YoY
-24.91%
NP Margin | ROE
7.47% | 7.71%
F.Y. | Ann. Date
31-Dec-2023 | 22-Feb-2024
Revenue | NP to SH
822,584.000 | 63,932.000
RPS | P/RPS
85.51 Cent | 1.45
EPS | P/E | EY
6.64 Cent | 18.66 | 5.36%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
4.62% | -9.12%
NP Margin | ROE
7.77% | 9.23%
F.Y. | Ann. Date
30-Jun-2024 | 15-Aug-2024
Last 10 FY Result | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 822,584 | 748,028 | 704,727 | 696,717 | 639,175 | 569,902 | 576,462 | 498,722 | 467,987 | 312,940 | 270,680 | 176,961 | 16.58% | |
PBT | 84,122 | 60,522 | 63,267 | 84,851 | 82,983 | 76,157 | 70,809 | 59,666 | 51,796 | 31,479 | 49,755 | 46,509 | 3.47% | |
Tax | -20,190 | -11,084 | -10,622 | -14,739 | -17,300 | -17,547 | -15,536 | -12,025 | -9,696 | -4,653 | 0 | 0 | - | |
NP | 63,932 | 49,438 | 52,645 | 70,112 | 65,683 | 58,610 | 55,273 | 47,641 | 42,100 | 26,826 | 49,755 | 46,509 | 1.38% | |
- | ||||||||||||||
NP to SH | 63,932 | 49,438 | 52,645 | 70,112 | 65,683 | 58,610 | 55,273 | 47,641 | 42,492 | 27,115 | 38,775 | 35,271 | 4.54% | |
- | ||||||||||||||
Tax Rate | 24.00% | 18.31% | 16.79% | 17.37% | 20.85% | 23.04% | 21.94% | 20.15% | 18.72% | 14.78% | 0.00% | 0.00% | - | |
Total Cost | 758,652 | 698,590 | 652,082 | 626,605 | 573,492 | 511,292 | 521,189 | 451,081 | 425,887 | 286,114 | 220,925 | 130,452 | 19.56% | |
- | ||||||||||||||
Net Worth | 692,598 | 692,598 | 682,979 | 657,045 | 621,564 | 642,484 | 525,364 | 483,173 | 479,809 | 454,703 | 270,177 | 192,942 | 15.06% |
Dividend | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Div | 19,238 | 26,934 | 22,124 | 21,901 | 21,660 | 45,891 | 40,937 | 36,403 | 23,711 | 18,132 | 15,843 | 25,679 | -1.64% | |
Div Payout % | 30.09% | 54.48% | 42.03% | 31.24% | 32.98% | 78.30% | 74.06% | 76.41% | 55.80% | 66.87% | 40.86% | 72.81% | - |
Equity | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Worth | 692,598 | 692,598 | 682,979 | 657,045 | 621,564 | 642,484 | 525,364 | 483,173 | 479,809 | 454,703 | 270,177 | 192,942 | 15.06% | |
NOSH | 961,942 | 961,942 | 961,942 | 952,239 | 941,765 | 706,026 | 684,383 | 661,881 | 278,959 | 278,959 | 278,959 | 138,807 | 23.98% |
Ratio Analysis | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NP Margin | 7.77% | 6.61% | 7.47% | 10.06% | 10.28% | 10.28% | 9.59% | 9.55% | 9.00% | 8.57% | 18.38% | 26.28% | - | |
ROE | 9.23% | 7.14% | 7.71% | 10.67% | 10.57% | 9.12% | 10.52% | 9.86% | 8.86% | 5.96% | 14.35% | 18.28% | - |
Per Share | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RPS | 85.51 | 77.76 | 73.26 | 73.17 | 67.87 | 80.72 | 84.49 | 75.35 | 167.76 | 112.18 | 162.30 | 127.49 | -5.96% | |
EPS | 6.64 | 5.14 | 5.49 | 7.39 | 6.98 | 8.46 | 8.25 | 7.26 | 15.09 | 9.62 | 19.17 | 25.41 | -15.64% | |
DPS | 2.00 | 2.80 | 2.30 | 2.30 | 2.30 | 6.50 | 6.00 | 5.50 | 8.50 | 6.50 | 9.50 | 18.50 | -20.66% | |
NAPS | 0.72 | 0.72 | 0.71 | 0.69 | 0.66 | 0.91 | 0.77 | 0.73 | 1.72 | 1.63 | 1.62 | 1.39 | -7.18% |
Adjusted Per Share Value based on latest NOSH - 961,942 | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RPS | 85.51 | 77.76 | 73.26 | 72.43 | 66.45 | 59.24 | 59.93 | 51.85 | 48.65 | 32.53 | 28.14 | 18.40 | 16.58% | |
EPS | 6.64 | 5.14 | 5.49 | 7.29 | 6.83 | 6.09 | 5.75 | 4.95 | 4.42 | 2.82 | 4.03 | 3.67 | 4.57% | |
DPS | 2.00 | 2.80 | 2.30 | 2.28 | 2.25 | 4.77 | 4.26 | 3.78 | 2.46 | 1.88 | 1.65 | 2.67 | -1.64% | |
NAPS | 0.72 | 0.72 | 0.71 | 0.683 | 0.6462 | 0.6679 | 0.5461 | 0.5023 | 0.4988 | 0.4727 | 0.2809 | 0.2006 | 15.06% |
Price Multiplier on Financial Quarter End Date | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Date | 28/06/24 | 28/06/24 | 29/12/23 | 30/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 29/12/17 | 30/12/16 | 31/12/15 | 31/12/14 | - | |
Price | 1.26 | 1.26 | 1.26 | 1.61 | 1.68 | 3.38 | 1.42 | 0.95 | 2.53 | 1.98 | 2.62 | 2.50 | - | |
P/RPS | 1.47 | 1.62 | 1.72 | 2.20 | 2.48 | 4.19 | 1.68 | 1.26 | 1.51 | 1.76 | 1.61 | 1.96 | -1.43% | |
P/EPS | 18.96 | 24.52 | 23.02 | 21.87 | 24.09 | 40.72 | 17.53 | 13.20 | 16.61 | 20.37 | 11.27 | 9.84 | 9.89% | |
EY | 5.27 | 4.08 | 4.34 | 4.57 | 4.15 | 2.46 | 5.70 | 7.58 | 6.02 | 4.91 | 8.87 | 10.16 | -9.01% | |
DY | 1.59 | 2.22 | 1.83 | 1.43 | 1.37 | 1.92 | 4.23 | 5.79 | 3.36 | 3.28 | 3.63 | 7.40 | -14.37% | |
P/NAPS | 1.75 | 1.75 | 1.77 | 2.33 | 2.55 | 3.71 | 1.84 | 1.30 | 1.47 | 1.21 | 1.62 | 1.80 | -0.18% |
Price Multiplier on Announcement Date | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Date | 15/08/24 | 15/08/24 | 22/02/24 | 23/02/23 | 15/02/22 | 22/02/21 | 13/02/20 | 18/02/19 | 28/02/18 | 24/02/17 | 23/02/16 | 24/02/15 | - | |
Price | 1.17 | 1.17 | 1.21 | 1.65 | 1.60 | 3.42 | 1.64 | 1.03 | 2.97 | 2.23 | 2.61 | 2.92 | - | |
P/RPS | 1.37 | 1.50 | 1.65 | 2.26 | 2.36 | 4.24 | 1.94 | 1.37 | 1.77 | 1.99 | 1.61 | 2.29 | -3.57% | |
P/EPS | 17.60 | 22.77 | 22.11 | 22.41 | 22.94 | 41.20 | 20.24 | 14.31 | 19.50 | 22.94 | 11.23 | 11.49 | 7.53% | |
EY | 5.68 | 4.39 | 4.52 | 4.46 | 4.36 | 2.43 | 4.94 | 6.99 | 5.13 | 4.36 | 8.91 | 8.70 | -7.01% | |
DY | 1.71 | 2.39 | 1.90 | 1.39 | 1.44 | 1.90 | 3.66 | 5.34 | 2.86 | 2.91 | 3.64 | 6.34 | -12.52% | |
P/NAPS | 1.62 | 1.62 | 1.70 | 2.39 | 2.42 | 3.76 | 2.13 | 1.41 | 1.73 | 1.37 | 1.61 | 2.10 | -2.31% |
PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.
NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.
Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.
All figures in '000 unless specified.
Managed and operated by white haired people sitting in wheel chairs and using walking sticks. Most have prostate problems, waking few times at night to urinate. Some are waiting for stairways to Heavens........HOW COULD COMPANY BE AGGRESSIVE???
2023-10-08 13:10
3Q23 profits down 45% YoY....current BOD is a team of silver haired centennials in wheelchairs. Raising 2 Billion bonds for retirement benefits?
BOD too aggressive is bad, weak BOD is also bad.......take your pick.
2023-11-10 12:07
Pharma is dying, yet this ctnr with Management in wheelchairs cannot take advantage.
2023-12-02 09:04
This is just reaction to Covid case spike, after that fall back down. Nothing new and exciting on the horizon for pharma in the coming months especially when Pharmaniaga still in the dump and government cutting back on spending.
2023-12-15 16:03
Hope this collaboration can bring good revenue to the company for Fy2024 and so on
https://theedgemalaysia.com/node/692365
2024-01-15 17:14
Duopharma Biotech Bhd is likely to see a recovery in its consumer healthcare (CHC) segment, while sales to the government sector is also expected to increase in 2024.
https://www.thestar.com.my/business/business-news/2024/01/26/duopharma-earnings-set-to-improve-this-year
2024-01-30 17:36
This is my trading call dated 15 Dec 2020. Most of the time chart will tell the true story:
https://www.tradingview.com/chart/DPHARMA/5tKe08jN-Trend-Analysis/
For investment or trading ideas, please feel free to visit my chart gallery:
https://www.tradingview.com/u/Yang358/#published-charts
2024-01-31 17:43
I love astronomy so most of my calculation/logics actually somehow related to astrophysics and planetary orbit. Something to do with price resistance, time resistance and speed resistance.
2024-02-02 16:45
Duopharma Biotech Clinches MYR578 million Supply Deals
https://www.tradingview.com/news/mtnewswires.com:20240501:G2361746:0/
2024-05-02 09:21
Yuhoo!!! Finally Duo making big move. 1.40 seems reasonable figure to relief breath.
2024-05-02 19:09
Ayo!!! What has 600m contract do to the Duo's share price??? Sometime the illogical happen.....
2024-05-04 18:39
Keep & follow TP from OSK
https://klse.i3investor.com/web/pricetarget/research/71461
2 months ago
Haha unfortunately i'm closing my position with Dpharma, feels like watching paint dry. Anyways good luck guys.
1 month ago
I think they have. https://www.freemalaysiatoday.com/category/nation/2016/01/28/viagra-no-longer-hard-to-get/
1 month ago
Duopharma Biotech 2Q net profit up 33%, pays one sen dividend 🔥
https://theedgemalaysia.com/node/722957
1 week ago
100Mark
reaching 52 weeks low, time to grab a bit
2023-09-06 10:28